Sun Pharma在专利到期后, 获得印度批准, 用于体重管理。 Sun Pharma gets Indian approval for generic semaglutide, Noveltreat, for weight management, following patent expiry.

2026年3月关键专利到期后,Sun制药公司得到印度的管制批准,以品牌为Novelltreat的重量管理品牌,出售一种通用的硫酸盐,用于进行重量管理。 Sun Pharmaceutical has received Indian regulatory approval to sell a generic version of semaglutide under the brand name Noveltreat for weight management, following the expiration of key patents in March 2026. 该药物在印度经过第三阶段试验后核准,将分五剂提供,用于饮食和运动。 The drug, approved after a Phase III trial in India, will be available in five doses and is intended for use with diet and exercise. 在此之前,2025年12月批准对2型糖尿病进行硫酸盐配方(Sematrinity)。 This follows a prior December 2025 approval for a semaglutide formulation, Sematrinity, for type 2 diabetes. 这一举动加剧了印度市场对廉价GLP-1药品的竞争日益激烈,一些印度制造商准备推出类似产品。 The move adds to growing competition in India’s market for affordable GLP-1 drugs, with several Indian manufacturers preparing to launch similar products.